BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C059I2
Authority: BE; Belgium

Application number

BE2016C059C

Other languages

Dutch (nl)

Original Assignee

Novozymes Biopharma Dk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2016-11-04

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-04 Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As

2020-08-20 Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Hematology (AREA)

BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (zh)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US19938400P	2000-04-25	2000-04-25
US25693100P	2000-12-21	2000-12-21
EP06076852A EP1832599A3 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
EP01934875A EP1278767A4 (en)	2000-04-12	2001-04-12	ALBUMIN FUSED PROTEINS
EP08075909A EP2067488A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Publications (1)

Publication Number	Publication Date
BE2016C059I2 true BE2016C059I2 (zh)	2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C059C BE2016C059I2 (zh)	2000-04-12	2016-11-04

Country Status (10)

Country	Link
US (23)	US20040010134A1 (zh)
EP (21)	EP2067488A1 (zh)
JP (9)	JP2004506407A (zh)
AU (7)	AU2001266557A1 (zh)
BE (1)	BE2016C059I2 (zh)
CA (8)	CA2405709A1 (zh)
DK (2)	DK2236152T3 (zh)
ES (2)	ES2484966T3 (zh)
FR (1)	FR16C0043I2 (zh)
WO (7)	WO2001079442A2 (zh)

Families Citing this family (664)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2001034769A2 (en) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	24 human secreted proteins
WO2001034626A1 (en) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	28 human secreted proteins
WO2001034627A1 (en) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	28 human secreted proteins
WO2002028877A1 (en) *	2000-09-29	2002-04-11	Human Genome Sciences, Inc.	24 human secreted proteins
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (de) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Humanes und murines Semaphorin L
US20030170794A1 (en) *	1997-09-18	2003-09-11	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2330527A1 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corporation	Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
AU773428B2 (en)	1998-10-13	2004-05-27	Peptide Biosciences, Inc.	Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
ES2402878T3 (es) *	1999-05-05	2013-05-10	Phylogica Limited	Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
AU1438001A (en) *	1999-10-29	2001-05-14	Human Genome Sciences, Inc.	27 human secreted proteins
CA3016482A1 (en)	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
AU784285B2 (en)	1999-12-24	2006-03-02	Genentech Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2067488A1 (en) *	2000-04-12	2009-06-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
JP2003532417A (ja) *	2000-05-12	2003-11-05	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	Ｆ−ｂｏｘ含有タンパク質
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
CA2412377A1 (en)	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	B7-related nucleic acids and polypeptides and their uses for immunomodulation
AU2001275401A1 (en) *	2000-06-08	2001-12-17	Incyte Genomics, Inc.	Intracellular signaling proteins
MXPA02012717A (es) *	2000-06-21	2003-09-22	Amgen Inc	Polipeptidos estromaticos-1 del colon, epiteliales, secretados, acidos nucleicos que los codifican y sus usos.
AU2001229507A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	21 human secreted proteins
AU2001229509A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	11 human secreted proteins
CA2419306A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	23 human secreted proteins
AU2001232835A1 (en) *	2000-08-28	2002-03-13	Human Genome Sciences, Inc.	18 human secreted proteins
CA2420192A1 (en) *	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 human secreted proteins
WO2002031111A2 (en) *	2000-10-12	2002-04-18	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7074913B2 (en)	2000-12-05	2006-07-11	Wisconsin Alumni Research Foundation	Receptor for B anthracis toxin
CN1483041A (zh)	2000-12-07	2004-03-17		Glp-1融合蛋白
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
WO2002053737A1 (fr) *	2000-12-28	2002-07-11	Asahi Kasei Kabushiki Kaisha	Gene d'activation de nf-kb
EP1368468A4 (en) *	2001-02-23	2005-02-16	Human Genome Sciences Inc	83 HUMAN SECRETED PROTEINS
EP1365801A4 (en) *	2001-03-08	2004-10-13	Nuvelo Inc	METHODS AND MATERIALS RELATING TO FIBULIN-RELATED POLYPEPTIDES AND POLYNUCLEOTIDES
US7736654B2 (en)	2001-04-10	2010-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7507413B2 (en) *	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US7250495B2 (en)	2001-06-20	2007-07-31	Genentech, Inc.	PRO20044 polypeptides
US20040234537A1 (en) *	2001-07-06	2004-11-25	Lydie Bougueleret	Carcinoma-related peptides
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
WO2003030821A2 (en) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (de)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) *	2001-11-16	2003-11-21	신코엠 주식회사	반도체 메모리 장치
DE60231057D1 (de)	2001-12-17	2009-03-19	Serono Lab	Chemokine mutanten, die als chemokine antagonisten wirken
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
CA2471363C (en) *	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
WO2003066078A1 (en) *	2002-02-07	2003-08-14	Delta Biotechnology Limited	Hiv inhibiting proteins
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
DE10205520A1 (de) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
KR20040096592A (ko) *	2002-02-21	2004-11-16	와이어쓰	폴리스타틴 도메인을 포함하는 단백질
WO2003075742A2 (en) *	2002-03-05	2003-09-18	Merck & Co., Inc.	Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
JP4585766B2 (ja) *	2002-04-15	2010-11-24	アメリカンナショナルレッドクロス	混合物中のリガンドおよび標的を検出する方法
US7319138B2 (en)	2002-04-18	2008-01-15	The General Hospital Corporation	Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) *	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DE60333758D1 (de)	2002-06-07	2010-09-23	Dyax Corp	Prevention und Verringerung von Ischemia
DK1531850T3 (da) *	2002-06-07	2012-06-04	Zymogenetics Inc	Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN101172091B (zh) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
CN1241946C (zh)	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
KR100628024B1 (ko) *	2002-07-03	2006-09-26	(주)넥스젠	식물에서 상피세포재생인자 및 인간 혈청 알부민을포함하는 융합 폴리펩타이드의 생산 방법
CA2489588A1 (en) *	2002-07-08	2004-01-15	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
CA2493263A1 (en) *	2002-07-22	2004-01-29	Yamanouchi Pharmaceutical Co., Ltd.	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
KR20050065519A (ko) *	2002-08-07	2005-06-29	델타 바이오테크놀로지 리미티드	알부민-융합 섬모 신경영양 인자
US20060129082A1 (en) *	2002-08-13	2006-06-15	Jacek Rozga	Selective plasma exchange therapy
DK2386310T3 (en)	2002-08-28	2019-02-25	Dyax Corp	Methods of preserving organs and tissues
US20040115194A1 (en) *	2002-09-06	2004-06-17	Yi Wang	Method of treatment of asthma using antibodies to complement component C5
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) *	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
WO2004027064A2 (en) *	2002-09-18	2004-04-01	Centre Hospitalier De L'universite De Montreal (Chum)	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003292273A1 (en) *	2002-12-20	2004-07-14	Karolinska Institutet Innovations Ab	Asthma susceptibility locus
CA2511522A1 (en) *	2002-12-26	2004-07-15	Takeda Pharmaceutical Company Limited	Novel proteins and use thereof
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
PT1592786E (pt) *	2003-02-11	2012-01-19	Shire Human Genetic Therapies	Diagnóstico e tratamento da deficiência de múltiplas sulfatases e outras utilizando uma enzima geradora de formilglicina (fge)
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220459B2 (en) *	2003-03-12	2010-08-05	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082640A2 (en) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Human serum albumin conjugates with therapeutic compounds
ATE514718T1 (de) *	2003-04-04	2011-07-15	Univ Lausanne	Peptabody für krebsbehandlung
WO2004091510A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Recombinant il-9 antibodies and uses thereof
WO2004094589A2 (en) *	2003-04-18	2004-11-04	Incyte Corporation	Secreted proteins
WO2004101620A2 (en) *	2003-05-01	2004-11-25	Compound Therapeutics, Inc.	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP4817233B2 (ja) *	2003-06-30	2011-11-16	学校法人日本大学	細胞外基質沈着タンパク質
CA2532250A1 (en)	2003-07-15	2005-02-03	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
RS53073B (en)	2003-11-04	2014-04-30	Novartis Vaccines And Diagnostics Inc.	USE OF ANTAGONISTIC ANTI-CD40 MONOCLONAL ANTIBODIES
WO2005054286A2 (en) *	2003-12-03	2005-06-16	Delta Biotechnology Limited	Interleukin-11 fusion proteins
CN100379762C (zh) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
WO2005058961A2 (en)	2003-12-12	2005-06-30	Amgen Inc.	Antibodies specific for human galanin, and uses thereof
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
EP1712619A4 (en) *	2003-12-24	2008-01-02	Takeda Pharmaceutical	MEANS FOR PREVENTING / CUREING CANCER
KR101184391B1 (ko) *	2004-02-09	2013-03-14	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
SE0400489D0 (sv) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
EP1721008B1 (en) *	2004-03-03	2010-02-24	EVOTEC Neurosciences GmbH	Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
WO2005091891A2 (en) *	2004-03-11	2005-10-06	Kythera Biopharmaceuticals, Inc.	Compositions and methods for preventing and treating skin and hair conditions
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
CN102746401A (zh)	2004-03-12	2012-10-24	瓦斯基因治疗公司	结合ephb4、抑制血管发生和肿瘤生长的抗体
US9592277B2 (en)	2004-04-14	2017-03-14	Avirid, Inc.	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
PT2100904E (pt) *	2004-04-23	2010-09-24	Conjuchem Biotechnologies Inc	Fase sólida para utilização num método para a purificação de conjugados de albumina
KR100599454B1 (ko) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	종양 억제자로 작용하는 ａｉｍ3의 신규 용도
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8008020B2 (en) *	2004-06-03	2011-08-30	Vermillion, Inc.	Biomarkers for peripheral artery disease
WO2006009825A1 (en) *	2004-06-17	2006-01-26	Virun, Inc.	Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
EP1773375A1 (en)	2004-07-14	2007-04-18	University of Utah Research Foundation	Netrin-related compositions and uses
CN102680686A (zh) *	2004-08-13	2012-09-19	千年药品公司	用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
AU2005286770A1 (en)	2004-09-21	2006-03-30	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2581423A1 (en) *	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (en) *	2004-10-01	2006-04-13	Cell Ionix, Inc.	Method and formulation for stem cells’ stimulation
AU2005295038B2 (en)	2004-10-06	2012-05-17	Mayo Foundation For Medical Education And Research	B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006042197A2 (en) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Use of del-1 in hair, bone and cartilage regeneration
CN101080420A (zh)	2004-10-25	2007-11-28	免疫系统密钥有限公司	胸腺特异性蛋白质
KR100583350B1 (ko) *	2004-11-03	2006-06-05	(주)넥스젠	Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
US7741455B2 (en) *	2004-11-09	2010-06-22	Ares Trading Sa	Method for purifying FSH
DK2330200T3 (en)	2004-12-23	2017-07-24	Albumedix As	GENE EXPRESSION TECHNIQUE
EP1835929B8 (en)	2005-01-06	2016-07-27	Novo Nordisk A/S	Anti-kir combination treatments and methods
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
WO2006089133A2 (en)	2005-02-15	2006-08-24	Duke University	Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
WO2006107611A2 (en) *	2005-03-23	2006-10-12	Wyeth	Detection of an immune response to gdf-8 modulating agents
WO2006102574A2 (en) *	2005-03-23	2006-09-28	Wyeth	Detection of gdf-8 modulating agents
US8034326B2 (en)	2005-04-18	2011-10-11	Novo Nordisk A/S	IL-21 variants
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
ES2417065T3 (es)	2005-04-26	2013-08-05	Trion Pharma Gmbh	Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP2221316A1 (en)	2005-05-05	2010-08-25	Duke University	Anti-CD19 antibody therapy for autoimmune disease
EP1951749A2 (en) *	2005-05-12	2008-08-06	Zymogenetics, Inc.	Methods of using phhla2 to co-stimulate t-cells
WO2006133396A2 (en)	2005-06-08	2006-12-14	Dana-Farber Cancer Institute	Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
WO2007014167A2 (en) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
PL1919503T3 (pl)	2005-08-10	2015-04-30	Macrogenics Inc	Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
PL1917276T3 (pl) *	2005-08-26	2018-08-31	Ares Trading S.A.	Sposób wytwarzania glikozylowanego interferonu beta
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US20070191272A1 (en) *	2005-09-27	2007-08-16	Stemmer Willem P	Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
JP2009509564A (ja) *	2005-10-03	2009-03-12	アストラゼネカ・アクチエボラーグ	血漿中半減期が調節された融合タンパク質
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
US8604175B2 (en) *	2005-12-09	2013-12-10	Ares Trading S.A.	Method for purifying FSH or a FSH mutant
WO2007075326A2 (en) *	2005-12-09	2007-07-05	Seattle Genetics, Inc.	Methods of using cd40 binding agents
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009520469A (ja) *	2005-12-22	2009-05-28	コンジュクヘムビオテクフノロギエスインコーポレイテッド	アルブミンと治療薬との前もって形成された抱合体の産生のための方法
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
EP1989326A4 (en)	2006-01-17	2009-09-30	Health Research Inc	BIO-HETERODUPLEX TRACKING TEST
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) *	2006-02-16	2007-08-30	Massachusetts Eye & Ear Infirmary	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2738178A1 (en)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antibody purification
PL2007885T3 (pl) *	2006-04-11	2010-12-31	Csl Behring Gmbh	Sposób zwiększania odzysku peptydów terapeutycznych in vivo
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
US8334365B2 (en) *	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
KR101641899B1 (ko) *	2006-06-14	2016-08-01	체에스엘 베링 게엠베하	혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) *	2006-06-14	2007-12-19	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
WO2008007146A1 (en) *	2006-07-13	2008-01-17	Upperton Limited	Process for preparing particles of proteinaceous material
AU2007278994B2 (en)	2006-07-24	2013-08-15	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
US20090208480A1 (en) *	2006-08-04	2009-08-20	Yue Huang	Long half-life recombinant butyrylcholinesterase
MX2009002547A (es) *	2006-09-06	2009-06-19	Phasebio Pharmaceuticals Inc	Composiciones terapeuticas de peptido de fusion.
JP5840345B2 (ja)	2006-09-08	2016-01-06	アンブルックス, インコーポレイテッドAmbrx, Inc.	修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7910102B2 (en)	2006-10-25	2011-03-22	Amgen Inc.	Methods of using conjugated toxin peptide therapeutic agents
US8475784B2 (en)	2006-10-26	2013-07-02	Novo Nordisk A/S	IL-21 variants
US20100136028A1 (en)	2006-11-07	2010-06-03	Sparrow Carl P	Antagonists of pcsk9
JP5492563B2 (ja)	2006-12-12	2014-05-14	バイオレクシスファーマシューティカルコーポレーション	トランスフェリン融合タンパク質ライブラリー
WO2008074840A2 (en)	2006-12-19	2008-06-26	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2557090A3 (en)	2006-12-19	2013-05-29	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
KR101542752B1 (ko) *	2006-12-22	2015-08-10	체에스엘 베링 게엠베하	연장된 생체내 반감기를 갖는 변형된 응고 인자
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
EP2423219B1 (en)	2007-01-30	2015-04-29	Epivax, Inc.	Regulatory T cell epitopes, compositions and uses thereof
DK2526962T3 (da)	2007-02-12	2019-10-07	Csl Behring Gmbh	Therapeutic application of Kazal-type serine protease inhibitors
CA2680832A1 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
CA2685465C (en)	2007-05-07	2020-02-25	Medimmune, Llc	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX376656B (es)	2007-05-14	2025-03-07	Kyowa Kirin Co Ltd	Metodos para reducir niveles de basófilos.
JP5591691B2 (ja)	2007-05-22	2014-09-17	アムジエン・インコーポレーテツド	生物活性を有する融合タンパク質を作製するための組成物及び方法
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
US8153595B2 (en)	2007-07-13	2012-04-10	The Johns Hopkins University	B7-DC variants immunogenic compositions and methods of use thereof
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
AU2008287340A1 (en) *	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
CN104017079B (zh)	2007-08-29	2017-01-04	塞诺菲-安万特股份有限公司	人源化的抗-cxcr5抗体、其衍生物及它们的应用
JP2009055838A (ja) *	2007-08-31	2009-03-19	Nipro Corp	融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
CA2699944C (en) *	2007-09-21	2017-11-14	The Regents Of The University Of California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
US20100249381A1 (en) *	2007-10-22	2010-09-30	David Delvaille	Method for Purifying FC-Fusion Proteins
CA2701221A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
EP2225275A4 (en)	2007-11-28	2013-04-03	Medimmune Llc	PROTEIN FORMULATION
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN104788563A (zh)	2007-12-21	2015-07-22	米迪缪尼有限公司	白介素-4受体α(IL-4Rα)-173的结合成员
US20100311072A1 (en) *	2008-01-28	2010-12-09	Bristol-Myers Squibb Company	Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
US20110020325A1 (en) *	2008-02-29	2011-01-27	Kwon Eugene D	Methods for reducing granulomatous inflammation
JP5020135B2 (ja) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	携帯端末装置およびコンピュータプログラム
CN102065903B (zh)	2008-04-01	2015-02-18	诺沃-诺迪斯克有限公司	胰岛素清蛋白缀合物
CA2720763A1 (en)	2008-04-07	2009-10-15	Ablynx Nv	Amino acid sequences directed against the notch pathways and uses thereof
PL2439212T3 (pl)	2008-05-02	2017-06-30	Novartis Ag	Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
EP2291523B1 (en) *	2008-06-24	2014-12-17	CSL Behring GmbH	Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
EP2313093A4 (en) *	2008-07-10	2012-03-28	Angion Biomedica Corp	METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
AU2009273251B2 (en)	2008-07-22	2014-12-18	Ablynx Nv	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
BRPI0916668B1 (pt)	2008-08-05	2021-12-28	Novartis Ag	Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
EP2328920A2 (en) *	2008-08-25	2011-06-08	Amplimmune, Inc.	Targeted costimulatory polypeptides and methods of use to treat cancer
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
US8163497B2 (en)	2008-09-07	2012-04-24	Glyconex Inc.	Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
ES2719496T3 (es)	2008-11-12	2019-07-10	Medimmune Llc	Formulación de anticuerpo
BRPI0921586A2 (pt) *	2008-11-18	2019-09-24	Merrimack Pharmaceuticals Inc	articuladores de albumina de soro humana e conjugados destes
DK2370593T3 (en)	2008-11-28	2016-07-04	Univ Emory	A method for determining the effect of PD-1 Antagonists
MY188826A (en) *	2008-12-09	2022-01-06	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
US8748115B2 (en)	2008-12-12	2014-06-10	Merck Sharp & Dohme Corp.	PCSK9 immunoassay
CN102307594A (zh)	2009-01-06	2012-01-04	戴埃克斯有限公司	用激肽释放酶抑制剂治疗粘膜炎
EA201190079A1 (ru)	2009-01-16	2013-02-28	Тева Фармасьютикал Индастриз, Лтд.	Новые стабильные составы рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN116925238A (zh)	2009-02-03	2023-10-24	阿穆尼克斯制药公司	延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
WO2010092135A2 (en)	2009-02-11	2010-08-19	Novozymes Biopharma Uk Ltd.	Albumin variants and conjugates
AU2010226392B9 (en)	2009-03-20	2014-05-22	Amgen Inc.	Selective and potent peptide inhibitors of Kv1.3
WO2010128143A1 (en)	2009-05-07	2010-11-11	Novozymes Biopharma Dk A/S	Method of controlling o-linked glycosylation of antibodies
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
WO2010138555A2 (en) *	2009-05-26	2010-12-02	University Of Florida Research Foundation, Inc.	Small peptide expression system in mammalian cells
NZ596778A (en)	2009-06-08	2013-11-29	Amunix Operating Inc	Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CA2769822C (en)	2009-08-13	2019-02-19	The Johns Hopkins University	Methods of modulating immune function
US20120148557A1 (en)	2009-08-20	2012-06-14	Ulrich Kronthaler	Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
US9062299B2 (en)	2009-08-24	2015-06-23	Amunix Operating Inc.	Coagulation factor IX compositions and methods of making and using same
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en)	2009-10-02	2011-08-11	Boehringer Ingelheim International Gmbh	Dll4-binging molecules
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
NO2486141T3 (zh)	2009-10-07	2018-06-09
WO2011051278A1 (en) *	2009-10-26	2011-05-05	Externautics S.P.A.	Lung tumor markers and methods of use thereof
CN102596249A (zh)	2009-10-30	2012-07-18	默沙东公司	Ax1和ax189 pcsk9拮抗剂和变体
BR112012009450A2 (pt)	2009-10-30	2017-05-23	Novozymes Biopharma Dk As	variantes de albumina
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
EP2493507A4 (en)	2009-10-30	2013-11-20	Merck Sharp & Dohme	AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011060528A1 (en) *	2009-11-17	2011-05-26	Universite De Montreal	Heteropeptides useful for reducing nonspecific adsorption
US9050318B2 (en)	2009-12-06	2015-06-09	Biogen Idec Hemophilia Inc.	Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
MX2012006462A (es)	2009-12-08	2012-10-03	Teva Pharma	Fusiones de albumina bche para el tratamiento de abuso de cocaina.
EP3309176A1 (en)	2009-12-14	2018-04-18	Ablynx N.V.	Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
EP2516664B1 (en)	2009-12-21	2015-07-22	Pharmathene Inc.	Recombinant butyrylcholinesterases and truncates thereof
SMT201800552T1 (it)	2010-01-06	2018-11-09	Dyax Corp	Proteine che legano la callicreina plasmatica
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
JP5980689B2 (ja)	2010-01-22	2016-08-31	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	安定な成長ホルモン化合物
TWI508737B (zh)	2010-01-22	2015-11-21	諾佛儂迪克股份有限公司	具有延長的活體內功效的生長激素
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP2547328B1 (en) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Ccr7 ligand delivery and co-delivery in immunotherapy
EP2542579A1 (en)	2010-03-03	2013-01-09	Boehringer Ingelheim International GmbH	Biparatopic abeta binding polypeptides
EP2371857A1 (en)	2010-04-01	2011-10-05	CSL Behring GmbH	Factor XII inhibitors for treating interstitial lung disease
EP2556087A1 (en)	2010-04-09	2013-02-13	Novozymes Biopharma DK A/S	Albumin derivatives and variants
EP2566892B1 (en)	2010-05-06	2017-12-20	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
JP2013527761A (ja)	2010-05-06	2013-07-04	ノバルティスアーゲー	治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
NZ603570A (en)	2010-05-20	2014-12-24	Ablynx Nv	Biological materials related to her3
CN103140237A (zh)	2010-07-09	2013-06-05	比奥根艾迪克依蒙菲利亚公司	因子ix多肽及其使用方法
US9611310B2 (en)	2010-07-09	2017-04-04	Bioverativ Therapeutics Inc.	Systems for factor VIII processing and methods thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US9518087B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
WO2012022814A1 (en)	2010-08-20	2012-02-23	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
AU2011293127B2 (en)	2010-08-27	2016-05-12	Abbvie Stemcentrx Llc	Notum protein modulators and methods of use
KR20140014064A (ko)	2010-09-03	2014-02-05	스템 센트알엑스 인코포레이티드	신규한 조절 인자 및 사용 방법
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
SG188591A1 (en)	2010-09-22	2013-04-30	Amgen Inc	Carrier immunoglobulins and uses thereof
ES2630031T3 (es) *	2010-09-28	2017-08-17	Aegerion Pharmaceuticals, Inc.	Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
DE19177059T1 (de)	2010-10-01	2021-10-07	Modernatx, Inc.	N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
CN103347893A (zh)	2010-11-01	2013-10-09	诺维信生物制药丹麦公司	白蛋白变体
JP6167040B2 (ja)	2010-11-05	2017-07-19	ザイムワークス，インコーポレイテッド	Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
US8591896B2 (en)	2010-11-08	2013-11-26	Novartis Ag	Chemokine receptor binding polypeptides
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
US9320812B2 (en)	2010-12-08	2016-04-26	Stemcentrx, Inc.	Modulators and methods of use
ES2689753T3 (es)	2010-12-28	2018-11-15	Sumitomo Dainippon Pharma Co., Ltd	Fármaco de diagnóstico y método de diagnóstico para la enfermedad de Alzheimer
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102320178B1 (ko)	2011-01-06	2021-11-02	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
CA2828405A1 (en)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale	Apoptosis-inducing molecules and uses therefor
WO2012116453A1 (en)	2011-03-03	2012-09-07	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9352016B2 (en)	2011-03-09	2016-05-31	Csl Behring Gmbh	Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
AR085911A1 (es)	2011-03-16	2013-11-06	Sanofi Sa	Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EA201391331A1 (ru)	2011-03-16	2014-02-28	Эмджен Инк.	Активные и селективные ингибиторы nav1.3 и nav1.7
US9340584B2 (en)	2011-03-29	2016-05-17	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
EP2691156A1 (en)	2011-03-30	2014-02-05	Boehringer Ingelheim International GmbH	Anticoagulant antidotes
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
RU2016147206A (ru)	2011-04-15	2018-10-19	Компуджен Лтд.	Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2515112B1 (en) *	2011-04-22	2015-08-12	Sysmex Corporation	Method for electrochemically detecting analyte
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012251583B2 (en)	2011-05-05	2017-06-08	Albumedix Ltd.	Albumin variants
WO2012170740A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
SI2717898T1 (sl)	2011-06-10	2019-07-31	Bioverativ Therapeutics Inc.	Spojine prokoagulantov in metode za njihovo uporabo
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
EP3569243A1 (en)	2011-06-28	2019-11-20	Inhibrx, LP	Serpin fusion polypeptides and methods of use thereof
MX2014000031A (es)	2011-07-01	2014-07-09	Bayer Ip Gmbh	Polipeptidos de fusion de relaxina y usos de los mismos.
SG10201606161UA (en)	2011-07-05	2016-09-29	Novozymes Biopharma Dk As	Albumin Formulation and Use
ES2732475T3 (es)	2011-07-08	2019-11-22	Aegerion Pharmaceuticals Inc	Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP2014529293A (ja)	2011-07-08	2014-11-06	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	レラキシンを放出する融合タンパク質およびその使用
CN103930134B (zh)	2011-07-18	2016-12-21	阿茨生物股份有限公司	长效促黄体激素(lh)化合物
PT2734552T (pt)	2011-07-22	2025-01-29	Csl Behring Gmbh	Anticorpos monoclonais inibidores do fator xii/xiia e suas utilizações
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20190099538A (ko)	2011-10-03	2019-08-27	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
AU2012332588B2 (en)	2011-11-01	2017-09-07	Bionomics, Inc.	Methods of blocking cancer stem cell growth
US9220774B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of treating cancer by administering anti-GPR49 antibodies
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
US9221906B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of inhibiting solid tumor growth by administering GPR49 antibodies
WO2013063702A1 (en)	2011-11-04	2013-05-10	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
EP2773669B1 (en)	2011-11-04	2018-03-28	Novartis AG	Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
WO2013075066A2 (en)	2011-11-18	2013-05-23	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
ES2758433T3 (es)	2011-12-05	2020-05-05	Novartis Ag	Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
AU2012349736A1 (en)	2011-12-05	2014-06-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
EP2791160B1 (en)	2011-12-16	2022-03-02	ModernaTX, Inc.	Modified mrna compositions
WO2013093762A1 (en)	2011-12-21	2013-06-27	Novartis Ag	Compositions and methods for antibodies targeting factor p
JP6127063B2 (ja)	2011-12-22	2017-05-10	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
RS59670B1 (sr)	2012-01-12	2020-01-31	Bioverativ Therapeutics Inc	Himerni polipeptidi faktora viii i njihove upotrebe
EP2623110A1 (en)	2012-01-31	2013-08-07	CSL Behring GmbH	Factor XII inhibitors for the treatment of neurological inflammatory disorders
EA028087B1 (ru)	2012-02-15	2017-10-31	Эколь Политекник Федераль Де Лозан	Связывающиеся с эритроцитами терапевтические средства
PL2814502T3 (pl) *	2012-02-15	2018-02-28	Csl Behring Gmbh	Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
HRP20221531T1 (hr)	2012-02-15	2023-02-17	Bioverativ Therapeutics Inc.	Pripravci faktora viii i postupci dobivanja i korištenja istih
HRP20190454T1 (hr)	2012-02-15	2019-05-03	Bioverativ Therapeutics Inc.	Rekombinantni faktor viii proteini
RU2014138474A (ru)	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
CN115925938A (zh)	2012-02-27	2023-04-07	阿布林克斯有限公司	Cx3cr1结合多肽
EP2825556B1 (en)	2012-03-16	2018-01-03	Albumedix A/S	Albumin variants
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US9550819B2 (en)	2012-03-27	2017-01-24	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
CA2868393A1 (en)	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
CN110078827A (zh) *	2012-04-27	2019-08-02	西托姆克斯治疗公司	结合表皮生长因子受体的可活化的抗体其使用方法
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
EP2847230B1 (en)	2012-05-10	2020-08-12	Zymeworks Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
CN104507310B (zh)	2012-05-30	2018-04-13	拜尔农作物科学股份公司	包括生物防治剂和杀昆虫剂的组合物
CN104883888B (zh)	2012-05-30	2017-11-24	拜尔农作物科学股份公司	包含生物防治剂和杀虫剂的组合物
CN108669088A (zh)	2012-05-30	2018-10-19	拜耳作物科学股份公司	包含生物防治剂和选自细胞壁合成抑制剂的杀真菌剂的组合物
TR201808095T4 (tr)	2012-05-30	2018-06-21	Bayer Cropscience Ag	Bir biyolojik kontrol ajanı ve bir insektisit içeren bileşimler.
CN104363758B (zh)	2012-05-30	2017-02-08	拜耳作物科学公司	包含生物防治剂和杀虫剂的组合物
BR112014029120A2 (pt)	2012-05-30	2017-06-27	Bayer Cropscience Ag	composição compreendendo um agente de controle biológico e um fungicida
EP2854551A1 (en)	2012-05-30	2015-04-08	Bayer Cropscience AG	Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii.
AR091195A1 (es)	2012-05-30	2015-01-21	Bayer Cropscience Ag	Composicion que comprende un agente de control biologico y un fungicida
JP2015519353A (ja)	2012-05-30	2015-07-09	バイエル・クロップサイエンス・アーゲーＢａｙｅｒＣｒｏｐｓｃｉｅｎｃｅＡｇ	生物的防除剤及び殺虫剤を含んでいる組成物
AR091200A1 (es)	2012-05-30	2015-01-21	Bayer Cropscience Ag	Composicion que comprende un agente de control biologico y un fungicida
US9596860B2 (en)	2012-05-30	2017-03-21	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of the mitosis and cell division or compounds having a multi-site action
CN104507318B (zh)	2012-05-30	2018-12-25	拜尔农作物科学股份公司	包括生物防治剂和来自呼吸链复合体iii抑制剂的杀真菌剂的组合物
US10202595B2 (en)	2012-06-08	2019-02-12	Bioverativ Therapeutics Inc.	Chimeric clotting factors
EP2858659B1 (en)	2012-06-08	2019-12-25	Bioverativ Therapeutics Inc.	Procoagulant compounds
KR101380740B1 (ko)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	이듀로네이트-2-설파타제의 정제
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EA201792485A3 (ru)	2012-07-11	2019-03-29	Амуникс Оперэйтинг Инк.	Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
AU2013289881B2 (en)	2012-07-13	2018-01-18	Zymeworks Bc Inc.	Multivalent heteromultimer scaffold design and constructs
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
AU2013309506A1 (en)	2012-09-02	2015-03-12	Abbvie Inc.	Methods to control protein heterogeneity
HK1213767A1 (zh)	2012-10-18	2016-07-15	Bioverativ Therapeutics Inc.	使用固定劑量凝血因子的方法
KR20150082422A (ko)	2012-11-08	2015-07-15	노보자임스 바이오파마 디케이 에이/에스	알부민 변이체
SG11201503593UA (en)	2012-11-13	2015-06-29	Biontech Ag	Agents for treatment of claudin expressing cancer diseases
SI2922554T1 (sl)	2012-11-26	2022-06-30	Modernatx, Inc.	Terminalno modificirana RNA
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
CN109517063B (zh)	2012-12-05	2022-07-01	诺华股份有限公司	靶向epo的抗体的组合物和方法
EP2935311B1 (en)	2012-12-20	2021-03-31	Amgen Inc.	Apj receptor agonists and uses thereof
MX2015009141A (es)	2013-01-15	2016-03-16	Teva Pharma	Formulaciones de albu-bche, preparacion y usos de las mismas.
KR101503907B1 (ko) *	2013-01-17	2015-03-20	서울대학교산학협력단	흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
CA2899170C (en)	2013-01-30	2022-08-02	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
AU2014214705A1 (en)	2013-02-11	2015-08-06	Bayer Cropscience Lp	Compositions comprising a streptomyces-based biological control agent and another biological control agent
PL3889173T3 (pl)	2013-02-15	2023-12-11	Bioverativ Therapeutics Inc.	Zoptymalizowany gen czynnika viii
AU2014217831A1 (en)	2013-02-16	2015-07-16	Albumedix Ltd.	Pharmacokinetic animal model
WO2014131865A1 (en)	2013-02-28	2014-09-04	Csl Behring Gmbh	Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
HK1216607A1 (zh)	2013-03-08	2016-11-25	Csl Behring Gmbh	治療和預防遠端缺血-再灌注損傷
US10981961B2 (en)	2013-03-11	2021-04-20	University Of Florida Research Foundation, Incorporated	Delivery of card protein as therapy for occular inflammation
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US10344060B2 (en)	2013-03-12	2019-07-09	Amgen Inc.	Potent and selective inhibitors of Nav1.7
US20160024181A1 (en)	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
WO2014165093A2 (en)	2013-03-13	2014-10-09	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP2970479B1 (en)	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US10588949B2 (en)	2013-03-15	2020-03-17	Bioverativ Therapeutics Inc.	Factor IX polypeptide formulations
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2978451B1 (en)	2013-03-29	2019-11-27	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
ES2841123T3 (es) *	2013-04-05	2021-07-07	Formulacion Del Compuesto De La Hormona De Crecimiento	Formulación del compuesto de la hormona de crecimiento
DK2796145T3 (da)	2013-04-22	2018-01-29	Csl Ltd	Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
UY35620A (es)	2013-06-21	2015-01-30	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CA2916399C (en)	2013-06-28	2022-08-02	Marc Nolte	Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP4368194A3 (en)	2013-06-28	2024-07-31	Bioverativ Therapeutics Inc.	Thrombin cleavable linker with xten and its uses thereof
CN104342420B (zh) *	2013-07-30	2017-09-15	惠觅宙	一种重组长效人透明质酸酶、其编码基因、生产方法及应用
EP3033098B1 (en)	2013-08-14	2022-06-22	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
TW202003554A (zh)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3035903B1 (en)	2013-08-20	2018-08-22	Anutra Medical, Inc.	Syringe fill system and method
EP3038634A4 (en)	2013-08-28	2017-10-11	AbbVie Stemcentrx LLC	Novel sez6 modulators and methods of use
BR112016004242A8 (pt)	2013-08-28	2018-06-12	Stemcentrx Inc	Métodos para conjugação sítio-específica de anticorpos e composições
US10611794B2 (en)	2013-09-25	2020-04-07	Bioverativ Therapeutics Inc.	On-column viral inactivation methods
CN103468662A (zh) *	2013-09-29	2013-12-25	惠觅宙	一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3470081A1 (en)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Methods for treating cancer in patients with elevated levels of bim
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions and methods for treatment of inflammatory bowel disease
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9540440B2 (en)	2013-10-30	2017-01-10	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DK3063275T3 (da)	2013-10-31	2019-11-25	Resolve Therapeutics Llc	Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
US10208102B2 (en) *	2013-11-01	2019-02-19	University Of Oslo	Albumin variants and uses thereof
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015089283A1 (en)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015104711A1 (en)	2014-01-09	2015-07-16	Hadasit Medical Research Services And Development Ltd.	Improved cell compositions and methods for cancer therapy
PH12016501323B1 (en)	2014-01-10	2022-04-29	Bioverativ Therapeutics Inc	Factor viii chimeric proteins and uses thereof
EP3107563B1 (en)	2014-02-21	2021-04-07	Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
AU2015229381B2 (en)	2014-03-11	2019-11-07	University Of Florida Research Foundation, Inc.	Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
US20170107294A1 (en) *	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
MX2016014306A (es)	2014-05-02	2017-06-12	Cerenis Therapeutics Holding Sa	Marcadores para terapia con lipoproteinas de alta densidad (hdl).
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
CN105198999A (zh) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	一种融合蛋白、其制备方法及其应用
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
JP6803236B2 (ja)	2014-06-10	2020-12-23	アムジェンインコーポレイテッド	アペリンポリペプチド
ES2886859T3 (es)	2014-06-18	2021-12-21	Csl Behring Gmbh	Terapia usando un inhibidor del factor xii en un trastorno neurotraumático
US20170204149A1 (en)	2014-06-23	2017-07-20	Novartis Ag	Hsa-gdf-15 fusion polypeptide and use thereof
TW201613958A (en)	2014-06-24	2016-04-16	Novo Nordisk As	MIC-1 fusion proteins and uses thereof
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
EA035581B1 (ru)	2014-07-30	2020-07-10	НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК.	Композиции и способы применения для лечения метаболических расстройств
KR102659872B1 (ko)	2014-08-07	2024-04-24	노파르티스 아게	안지오포이에틴-유사 4 항체 및 사용 방법
US9988443B2 (en)	2014-08-07	2018-06-05	Novartis Ag	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
RU2685869C1 (ru)	2014-08-22	2019-04-23	Нэшенл Ченг Кунг Юниверсити	Варианты дизинтегрина и их фармацевтическое применение
US9826743B2 (en)	2014-09-17	2017-11-28	Bayer Cropscience Lp	Compositions comprising recombinant bacillus cells and another biological control agent
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AU2015323769A1 (en)	2014-09-26	2017-04-13	Bayer Pharma Aktiengesellschaft	Stabilized adrenomedullin derivatives and use thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3207130B1 (en)	2014-10-14	2019-08-07	Halozyme, Inc.	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
PL3212226T3 (pl)	2014-10-31	2020-11-02	Ngm Biopharmaceuticals, Inc.	Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
JP6798993B2 (ja) *	2014-12-23	2020-12-09	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	ボツリヌス毒素プレフィルド容器
ES2846748T3 (es) *	2015-03-30	2021-07-29	Regeneron Pharma	Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
JP2016204292A (ja) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
ES2744342T3 (es) *	2015-04-29	2020-02-24	Mediolanum Farm S P A	Un receptor quimérico soluble de interleucina 10 y su uso terapéutico
WO2016195723A1 (en) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Methods of treatment for conditions mediated by substance p
AU2016273028B2 (en)	2015-06-05	2019-02-14	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
ES2671844B1 (es) *	2015-06-11	2019-03-22	Attwill Medical Solutions Inc	Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina.
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
CN107921096A (zh) *	2015-07-30	2018-04-17	恩多技术公司	用于胰腺癌或结肠癌治疗的集落刺激因子
WO2017021893A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
CA2994552A1 (en)	2015-08-06	2017-02-09	The Trustees Of The University Of Pennsylvania	Glucagon-like peptide 1 and use thereof in compositions for treating metabolic diseases
CA2989966C (en)	2015-08-20	2024-04-30	Albumedix A/S	Albumin variants and conjugates
JP6886920B2 (ja)	2015-09-08	2021-06-16	Ｊｃｒファーマ株式会社	新規なヒト血清アルブミン変異体
WO2017042701A1 (en)	2015-09-09	2017-03-16	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
LT3347377T (lt)	2015-09-09	2021-05-25	Novartis Ag	Užkrūčio liaukos stromos limfopoetiną (tslp) rišantys antikūnai ir antikūnų panaudojimo būdai
CN108430518A (zh)	2015-09-11	2018-08-21	小利兰·斯坦福大学托管委员会	生物相关正交细胞因子/受体对
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
PH12018501155B1 (en)	2015-12-04	2024-06-28	Boehringer Ingelheim Int	Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA201891388A1 (ru)	2015-12-11	2018-11-30	Дайэкс Корп.	Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
UY37030A (es)	2015-12-18	2017-07-31	Novartis Ag	Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
US20190000923A1 (en)	2015-12-22	2019-01-03	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017122130A1 (en)	2016-01-11	2017-07-20	Novartis Ag	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
US20210198368A1 (en)	2016-01-21	2021-07-01	Novartis Ag	Multispecific molecules targeting cll-1
SG10201913278PA (en)	2016-02-01	2020-02-27	Bioverativ Therapeutics Inc	Optimized factor viii genes
WO2017159540A1 (ja)	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	血清アルブミン－２０ｋ成長ホルモン融合タンパク質
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
MX2018011503A (es)	2016-03-31	2018-11-09	Ngm Biopharmaceuticals Inc	Proteinas de union y metodos de uso de las mismas.
AU2017247004B2 (en)	2016-04-06	2022-07-07	Csl Limited	Method of treating atherosclerosis
EP3448887A1 (en)	2016-04-27	2019-03-06	Novartis AG	Antibodies against growth differentiation factor 15 and uses thereof
LT3458478T (lt)	2016-05-18	2021-02-10	Boehringer Ingelheim International Gmbh	Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui
AU2017269496B2 (en)	2016-05-24	2021-03-25	Novo Nordisk A/S	MIC-1 compounds and use thereof
EP3471759A1 (en)	2016-06-15	2019-04-24	Novartis AG	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102446476B1 (ko) *	2016-07-08	2022-10-19	체에스엘 베링 렝나우 아게	사람에서의 장기-작용성 인자 ix의 피하 투여
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
WO2018024873A1 (en)	2016-08-05	2018-02-08	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en)	2016-08-23	2019-07-03	CSL Behring GmbH	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
EP3535585A1 (en)	2016-11-04	2019-09-11	Aarhus Universitet	Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
EP3541407A1 (en) *	2016-11-18	2019-09-25	Universitat de Barcelona	Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
MX2019006446A (es)	2016-12-02	2019-12-11	Bioverativ Therapeutics Inc	Métodos para inducir tolerancia inmunológica a factores de coagulación.
IL266972B2 (en)	2016-12-02	2024-04-01	Bioverativ Therapeutics Inc	Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
EP3562840A1 (en)	2016-12-16	2019-11-06	Biogen MA Inc.	Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2017383537B2 (en)	2016-12-23	2024-10-03	Novartis Ag	Methods of treatment with anti-Factor XI/XIa antibodies
US20180237787A1 (en)	2016-12-23	2018-08-23	President And Fellows Of Harvard College	Gene editing of pcsk9
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
EP3568411B1 (en)	2017-01-13	2024-03-06	Pietro P. Sanna	Methods and compositions for treating hpa hyperactivity
MX2019009063A (es)	2017-01-31	2019-10-21	Bioverativ Therapeutics Inc	Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
EP3580237B1 (en)	2017-02-08	2025-05-14	Novartis AG	Fgf21 mimetic antibodies and uses thereof
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018193033A1 (en)	2017-04-20	2018-10-25	Novo Nordisk A/S	Methods of purification of albumin fusion proteins
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
KR20200010468A (ko)	2017-05-24	2020-01-30	노파르티스 아게	항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
UA125761C2 (uk)	2017-05-31	2022-06-01	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Поліпептид, який перешкоджає передачі wnt-сигналів у пухлинних клітинах
US11253579B2 (en)	2017-06-16	2022-02-22	The University Of Chicago	Compositions and methods for inducing immune tolerance
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020525498A (ja)	2017-06-29	2020-08-27	ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト	血友病の予防的処置のための第ｉｘ因子およびヒトアルブミンを含む融合タンパク質に関する２１日の投与計画およびその方法
US20210346513A1 (en)	2017-08-04	2021-11-11	Amgen Inc.	Method of conjugation of cys-mabs
WO2019032898A1 (en)	2017-08-09	2019-02-14	Bioverativ Therapeutics Inc.	NUCLEIC ACID MOLECULES AND USES THEREOF
WO2019036605A2 (en)	2017-08-17	2019-02-21	Massachusetts Institute Of Technology	MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
CA3075686A1 (en)	2017-09-15	2019-03-21	Cedars-Sinai Medical Center	Methods for improving organ function in organ transplant patients
JP2020537668A (ja) *	2017-10-18	2020-12-24	シーエスエルリミティド	ヒト血清アルブミン変異体およびその使用
EP3700933A1 (en)	2017-10-25	2020-09-02	Novartis AG	Antibodies targeting cd32b and methods of use thereof
CN111479587B (zh)	2017-12-15	2024-01-09	杰特有限公司	FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
WO2019129221A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against tigit
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
US11713353B2 (en)	2018-01-15	2023-08-01	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against PD-1
WO2019152692A1 (en)	2018-02-01	2019-08-08	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing factor viii
US20210260210A1 (en)	2018-03-13	2021-08-26	Zymeworks Inc.	Anti-her2 biparatopic antibody-drug conjugates and methods of use
HRP20230984T1 (hr) *	2018-03-13	2023-12-08	Sepsia Therapeutics, S.L.	Peptidi koji vežu bakterije, za liječenje zaraznih bolesti i povezanih upalnih procesa
SG11202009017WA (en)	2018-03-28	2020-10-29	Bristol Myers Squibb Co	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US11958903B2 (en)	2018-03-30	2024-04-16	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against LAG-3 and uses thereof
KR102119197B1 (ko) *	2018-04-23	2020-06-05	주식회사 엘베이스	세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
CA3100007A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
JP7497340B2 (ja)	2018-05-14	2024-06-10	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能なインターロイキン１２ポリペプチド及びその使用方法
MA52630A (fr)	2018-05-18	2021-05-26	Bioverativ Therapeutics Inc	Procédés de traitement de l'hémophilie a
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3802611A2 (en)	2018-06-01	2021-04-14	Novartis AG	Binding molecules against bcma and uses thereof
EP3807321A4 (en)	2018-06-18	2022-03-02	Anwita Biosciences, Inc.	ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
WO2020010117A2 (en)	2018-07-03	2020-01-09	Bristol-Myers Squibb Company	Fgf21 formulations
CA3108799A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
HRP20250234T1 (hr)	2018-08-31	2025-04-11	Regeneron Pharmaceuticals, Inc.	Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela
EP3852874A1 (en) *	2018-09-17	2021-07-28	Kyoto University	Administration of an anti-c5 agent for treatment of hepatic injury or failure
CN113286812B (zh)	2018-09-27	2025-05-30	西里欧发展公司	掩蔽型细胞因子多肽
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
AU2019369403B2 (en) *	2018-10-29	2025-04-17	Spin Therapeutics, Llc	Compositions and methods for alpha-1-antitrypsin disorders
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
EP3887393A1 (en)	2018-11-26	2021-10-06	Novartis AG	Lpl-gpihbp1 fusion polypeptides
TW202039855A (zh)	2018-12-06	2020-11-01	美商百歐維拉提夫治療公司	表現因子ｉｘ之慢病毒載體的用途
EP3941580A1 (en)	2019-03-22	2022-01-26	Reflexion Pharmaceuticals, Inc.	D-peptidic compounds for vegf
WO2020198075A2 (en)	2019-03-22	2020-10-01	Reflexion Pharmaceuticals, Inc.	Multivalent d-peptidic compounds for target proteins
CN113874392A (zh)	2019-03-28	2021-12-31	丹尼斯科美国公司	工程化抗体
EA202192786A1 (ru)	2019-04-11	2022-01-11	Энджион Байомедика Корп.	Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
CN114450022A (zh)	2019-05-14	2022-05-06	狼人治疗公司	分离部分及其使用方法
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
CR20210576A (es)	2019-05-21	2021-12-15	Novartis Ag	Moléculas de unión a cd19 y usos de las mismas
WO2020242989A1 (en)	2019-05-24	2020-12-03	Sanofi	Methods for treating systemic sclerosis
CA3143584A1 (en)	2019-06-18	2020-12-24	Bayer Aktiengesellschaft	Adrenomedullin-analogues for long-term stabilization and their use
JP7671739B2 (ja)	2019-09-06	2025-05-02	ノバルティスアーゲー	治療用融合タンパク質
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US20210113634A1 (en)	2019-09-30	2021-04-22	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
KR20220083784A (ko)	2019-10-17	2022-06-20	제이씨알 파마 가부시키가이샤	혈청 알부민과 성장 호르몬의 융합 단백질의 제조 방법
KR20220095204A (ko)	2019-10-30	2022-07-06	제이씨알 파마 가부시키가이샤	혈청 알부민과 성장 호르몬의 융합 단백질을 함유하는 수성 의약 조성물
KR20220101147A (ko)	2019-11-14	2022-07-19	웨어울프 세라퓨틱스, 인크.	활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
EP4069200A1 (en)	2019-12-04	2022-10-12	Albumedix Ltd	Methods and compositions produced thereby
WO2021119534A2 (en)	2019-12-13	2021-06-17	Synthekine, Inc.	Il-2 orthologs and methods of use
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
US12358963B2 (en)	2019-12-24	2025-07-15	Juvena Therapeutics, Inc.	Regenerative polypeptides and uses thereof
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
BR112022020428A2 (pt)	2020-04-09	2023-03-07	Verve Therapeutics Inc	Edição base do angptl3 e métodos de uso do mesmo para tratamento de doenças
PH12022553153A1 (en)	2020-05-19	2024-02-26	Boehringer Ingelheim Int	Binding molecules for the treatment of cancer
EP4165181A2 (en)	2020-06-14	2023-04-19	Vertex Pharmaceuticals Incorporated	Complement factor i-related compositions and methods
CA3183557A1 (en)	2020-06-24	2021-12-30	Bioverativ Therapeutics Inc.	Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
US12110335B2 (en)	2020-10-21	2024-10-08	Boehringer Ingelheim International Gmbh	Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
CN116406374A (zh) *	2020-10-30	2023-07-07	深圳普罗吉医药科技有限公司	人血清白蛋白在治疗疾病中的应用
JP2023548529A (ja)	2020-11-06	2023-11-17	ノバルティスアーゲー	Ｃｄ１９結合分子及びその使用
TW202235431A (zh)	2020-11-25	2022-09-16	美商艾希利歐發展股份有限公司	腫瘤特異性可裂解連接子
CN114478800B (zh) *	2021-02-05	2022-10-11	华南理工大学	基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
AU2022224636A1 (en)	2021-02-19	2023-09-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies that neutralize sars-cov-2
TW202317625A (zh)	2021-06-17	2023-05-01	德商百靈佳殷格翰國際股份有限公司	新穎三特異性結合分子
JP2024525213A (ja)	2021-06-21	2024-07-10	ジュベナセラピューティクス，インク．	再生ポリペプチドおよびその使用
CN114133458B (zh) *	2021-12-08	2023-11-14	福州大学	一种在人血清白蛋白内部融合多肽的方法
PE20251172A1 (es)	2022-04-26	2025-04-23	Novartis Ag	Anticuerpos multiespecificos que se dirigen a il-13 e il-18
EP4554619A1 (en)	2022-07-15	2025-05-21	Danisco US Inc.	Methods for producing monoclonal antibodies
MA71446A (fr)	2022-07-15	2025-04-30	Boehringer Ingelheim International Gmbh	Molécules de liaison pour le traitement du cancer
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
AU2023407176A1 (en) *	2022-12-20	2025-05-29	CSL Innovation Pty Ltd	Fcrn antagonists and uses thereof
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations and uses thereof
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (de) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
CA1341567C (en)	1980-01-08	2008-02-19	Charles Weissmann	Dna sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NZ196706A (en)	1980-04-03	1988-01-08	Biogen Nv	Dna sequences, recombinant dna molecules and processes for producing fibroblast interferon-like polypeptides; pharmaceutical and veterinary compositions
DE3023787A1 (de)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
NZ198445A (en)	1980-09-25	1984-05-31	Genentech Inc	Production of human fibroblast interferon by recombinant dna technology
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
ATE12348T1 (de)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
DE3273787D1 (en)	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en)	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
CA1204682A (en)	1981-06-19	1986-05-20	Saran A. Narang	Adaptors, and synthesis and cloning of proinsulin genes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (en)	1981-11-12	1984-08-08	The Upjohn Company	Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (ja)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
EP0098876A1 (en)	1982-01-19	1984-01-25	Cetus Corporation	Multiclass hybrid interferons
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
CA1341562C (en)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
DE3377363D1 (en)	1982-03-31	1988-08-18	Ajinomoto Kk	Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
JPS5945835U (ja)	1982-09-16	1984-03-27	株式会社東芝	回路しや断器の消弧装置
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
DE3382547D1 (de)	1983-01-12	1992-05-27	Chiron Corp	Sekretorische expression in eukaryoten.
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
DK172738B1 (da)	1983-04-07	1999-06-21	Chiron Corp	Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
JPS60501140A (ja)	1983-04-22	1985-07-25	アムジエン	酵母による外因性ポリペプチドの分泌
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Slow release injectable insulin composition
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	雑種制御領域
ATE59966T1 (de)	1983-09-26	1991-02-15	Ehrenfeld Udo	Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
JPS60115528A (ja)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (ja)	1983-12-26	1985-07-20	Suntory Ltd	ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it)	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
CA1213537A (en)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Polypeptide expression method
FR2564106B1 (fr) *	1984-05-09	1988-04-22	Transgene Sa	Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da)	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (en)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Novel transformant and use thereof
US4736866A (en)	1984-06-22	1988-04-12	President And Fellows Of Harvard College	Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en) *	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (da)	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
FR2579224B1 (fr)	1985-03-25	1987-05-22	Genetica	Procede de preparation microbiologique de la serum-albumine humaine
US4751180A (en) *	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
DE3679343D1 (de)	1985-03-28	1991-06-27	Chiron Corp	Expression durch verwendung von fusionsgenen fuer proteinproduktion.
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
AU5890286A (en)	1985-06-17	1986-12-24	Genex Corp.	Cloned human serum albumin gene
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (ja)	1985-10-04	1994-03-16	中外製薬株式会社	白血球減少症治療剤
JPS6296086A (ja)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	複合プラスミド
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
EP0247091B1 (en)	1985-11-01	1993-09-29	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
CA1295563C (en)	1985-11-01	1992-02-11	Robert T. Garvin	Production of active proteins containing cystine residues
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (en)	1987-07-21	1992-02-11	Robert T. Garvin	Characterization and structure of genes for protease a and protease b from streptomyces griseus
JPH0780930B2 (ja)	1985-12-26	1995-08-30	三井石油化学工業株式会社	α−オレフインの重合方法
JPH0645551B2 (ja)	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
ES2039209T5 (es)	1986-01-22	1996-07-16	Chugai Pharmaceutical Co Ltd	Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
ATE74272T1 (de)	1986-01-22	1992-04-15	Chugai Pharmaceutical Co Ltd	Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (fr) *	1986-02-21	1989-10-20	Genetica	Procede de preparation de la serum albumine humaine mature
EP0237019A3 (en)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interferon conjugate and production thereof using recombinant gene
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IT1203758B (it)	1986-03-27	1989-02-23	Univ Roma	Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
DK179286D0 (da)	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
US4765980A (en) *	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (it) *	1986-06-20	1989-03-01	Sclavo Spa	Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (it)	1986-07-11	1988-11-16	Sclavo Spa	Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en)	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1988007057A1 (en)	1987-03-13	1988-09-22	Amgen Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
ES2052712T3 (es) *	1987-04-09	1994-07-16	Delta Biotechnology Ltd	Vector de levadura.
EP0682110A1 (en)	1987-04-22	1995-11-15	Chiron Corporation	Recombinant DNA encoding PDGF A-chain polypeptides
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
IE62458B1 (en)	1987-07-28	1995-02-08	Gist Brocades Nv	Kluyveromyces as a host strain
JPH0622784Y2 (ja)	1987-08-04	1994-06-15	東洋シヤッター株式会社	オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja)	1987-08-19	1997-07-09	株式会社ビタミン研究所	遺伝子封入リポソームの製法
SE459586B (sv)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
NZ226414A (en)	1987-10-02	1992-07-28	Genentech Inc	Cd4 peptide adhesion variants and their preparation and use
JPH0811074B2 (ja)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (ja)	1987-12-02	1998-08-27	株式会社ミドリ十字	異種蛋白質の製造方法、組換えｄｎａ、形質転換体
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
ZA89430B (en)	1988-01-22	1989-10-25	Gen Hospital Corp	Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (ja) *	1988-02-16	1989-09-25	Green Cross Corp:The	酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
ATE101620T1 (de)	1988-06-23	1994-03-15	Hoechst Ag	Mini-proinsulin, seine herstellung und verwendung.
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
PT90959B (pt)	1988-06-24	1995-05-04	Dow Chemical Co	Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
WO1989012631A1 (en)	1988-06-24	1989-12-28	The Dow Chemical Company	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
HU213571B (en) *	1988-07-23	1997-08-28	Delta Biotechnology Ltd	Process for producing peptides and dna sequences
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2635115B1 (fr)	1988-08-05	1992-04-03	Rhone Poulenc Sante	Procede de preparation de la serum albumine humaine a partir d'une levure
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0428615A4 (en)	1988-08-11	1991-11-13	California Biotechnology, Inc.	Method for stabilizing heterologous protein expression and vectors for use therein
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE768377T1 (de)	1988-09-02	1998-01-02	Dyax Corp	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (ja)	1988-10-06	1990-09-10	Tonen Corp	ヒト血清アルブミン断片
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JPH02117384A (ja)	1988-10-26	1990-05-01	Tonen Corp	酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
CA2345497A1 (en)	1988-10-28	1990-04-28	Genentech, Inc.	Growth hormone variants and method for forming growth hormone variants
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
ATE135370T1 (de)	1988-12-22	1996-03-15	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DK105489D0 (da) *	1989-03-03	1989-03-03	Novo Nordisk As	Polypeptid
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en) *	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
JPH04504246A (ja)	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン刺激ホルモン
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
ATE277193T1 (de)	1989-03-21	2004-10-15	Vical Inc	Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0392300T3 (da) *	1989-04-11	1992-09-28	Boehringer Ingelheim Int	Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
EP0395918A3 (en)	1989-04-13	1991-10-23	Vascular Laboratory, Inc.	Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
DE69031120T2 (de)	1989-05-19	1998-01-15	Genentech, Inc., South San Francisco, Calif.	Her2 extrazellulare domäne
DE69024261T2 (de)	1989-05-24	1996-07-18	Merck & Co Inc	Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
EP0429586B1 (en) *	1989-06-09	1995-08-02	Gropep Pty. Ltd.	Growth hormone fusion proteins
JPH0327320A (ja)	1989-06-26	1991-02-05	Ajinomoto Co Inc	ヒトｂ細胞分化因子医薬組成物
DE69029036T2 (de)	1989-06-29	1997-05-22	Medarex Inc	Bispezifische reagenzien für die aids-therapie
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) *	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CU22222A1 (es)	1989-08-03	1995-01-31	Cigb	Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
FR2650598B1 (fr) *	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
DK0489116T3 (da)	1989-08-22	1994-05-02	Immunex Corp	Fusionsproteiner omfattende GM-CSF og IL-3
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (en)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
JP3127158B2 (ja)	1989-10-05	2001-01-22	オプテイン，インコーポレイティド	新規の遺伝子及びポリペチドの無細胞合成並びに単離
FR2653020B1 (fr)	1989-10-17	1993-03-26	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
CA2044593C (en)	1989-11-03	2004-04-20	Kenneth L. Brigham	Method of in vivo delivery of functioning foreign genes
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
DK608589D0 (da)	1989-12-01	1989-12-01	Holm Arne	Kemisk fremgangsmaade
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5116944A (en) *	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
JPH03201987A (ja) *	1989-12-29	1991-09-03	Tonen Corp	ヒト血清アルブミン断片
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
ATE135044T1 (de) *	1990-01-25	1996-03-15	Univ Washington	Faktor x-laci-hybridprotein
JPH04211375A (ja)	1990-02-05	1992-08-03	Ajinomoto Co Inc	合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU7906691A (en)	1990-05-23	1991-12-10	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JPH06502987A (ja)	1990-07-10	1994-04-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｏ―グリコシル化ｉｆｎ―アルファ
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (it)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
CA2093022C (en)	1990-10-05	2005-02-22	Michael W. Fanger	Targeted immunostimulation with bispecific reagents
JPH07108232B2 (ja)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja)	1990-10-26	1994-10-12	株式会社カンセイ	エアバック制御装置
WO1992008802A1 (en)	1990-10-29	1992-05-29	Cetus Oncology Corporation	Bispecific antibodies, method of production, and uses thereof
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
FR2668368B1 (fr)	1990-10-30	1995-03-10	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
JPH0638771A (ja)	1990-10-31	1994-02-15	Tonen Corp	ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
DE69133340D1 (de)	1990-11-29	2003-12-18	Agronomique Inst Nat Rech	Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en)	1991-03-12	1992-09-13	Yasutaka Igari	Composition for sustained-release of erythropoietin
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
DE69229454T2 (de)	1991-03-28	2000-01-05	Merck & Co., Inc.	Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
DE69233750D1 (de)	1991-04-10	2009-01-02	Scripps Research Inst	Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
DE69214709T2 (de)	1991-04-26	1997-02-20	Surface Active Ltd	Neue Antikörper und Verfahren zu ihrer Verwendung
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
FR2676070B1 (fr)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisation.
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
EP0590067A1 (en)	1991-06-14	1994-04-06	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
FR2677996B1 (fr)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
WO1993000109A1 (en)	1991-06-28	1993-01-07	Genentech, Inc.	Method of stimulating immune response using growth hormone
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (ja)	1991-07-29	1993-11-09	Tonen Corp	改良された酵母発現系
WO1993003164A1 (en)	1991-07-31	1993-02-18	Rhone-Poulenc Rorer International (Holdings) Inc.	Transgenic protein production
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
DE69226197T2 (de) *	1991-11-08	1999-02-11	Somatogen, Inc., Boulder	Hämoglobine als arzneimittelabgabesystem
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
JPH07506720A (ja)	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	アルツハイマー病のトランスジェニック動物モデル
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (fr) *	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	Serum-albumine humaine, preparation et utilisation.
FR2686901A1 (fr)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr)	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
WO1993016185A2 (en)	1992-02-06	1993-08-19	Creative Biomolecules, Inc.	Biosynthetic binding protein for cancer marker
EP1306095A3 (en)	1992-03-05	2003-06-25	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
PL171749B1 (pl)	1992-06-09	1997-06-30	Hoppe Ag	Zamek zatrzaskowypopychacz , wspólpracujacy z lukowym wglebie- PL PL PL PL
SK155694A3 (en)	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	ヒト血清アルブミンの製造方法
FR2694294B1 (fr)	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Promoteur de levure et son utilisateur.
ATE359824T1 (de)	1992-07-31	2007-05-15	Genentech Inc	Wässrige formulierung enthaltend menschliches wachstumshormon
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4226971C2 (de) *	1992-08-14	1997-01-16	Widmar Prof Dr Tanner	Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
WO1994008599A1 (en) *	1992-10-14	1994-04-28	The Regents Of The University Of Colorado	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (fr)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en)	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) *	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
NZ250844A (en)	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1994024160A2 (en)	1993-04-21	1994-10-27	Brigham And Women's Hospital	Erythropoietin muteins with enhanced activity
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
AU703110B2 (en) *	1993-05-21	1999-03-18	Novo Nordisk A/S	Modified factor VII
JP3626187B2 (ja)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	遺伝子治療に適するプラスミド
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (da) *	1993-07-08	1993-07-08	Novo Nordisk As	Peptid
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
ES2167373T3 (es)	1993-08-09	2002-05-16	Edward Baral	Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.
CN1057534C (zh)	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
AU7531094A (en)	1993-08-24	1995-03-21	Novo Nordisk A/S	Protracted glp-1
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (en)	1993-12-08	1995-06-15	Genzyme Corporation	Process for generating specific antibodies
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1272295A (en)	1993-12-17	1995-07-03	Novo Nordisk A/S	Proinsulin-like compounds
DK144093D0 (zh)	1993-12-23	1993-12-23	Novo Nordisk As
ATE243745T1 (de)	1994-01-31	2003-07-15	Univ Boston	Bibliotheken aus polyklonalen antikörpern
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) *	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
WO1996003144A1 (en)	1994-07-27	1996-02-08	The Council Of The Queensland Institute Of Medical Research	Polyepitope vaccines
JPH0853500A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	融合タンパク質および該タンパク質をコードする遺伝子
JPH0851982A (ja)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	ヒト血清アルブミンをコードする改変された遺伝子
JPH0859509A (ja)	1994-08-16	1996-03-05	Teijin Ltd	サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726576B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
KR100507431B1 (ko)	1994-11-07	2005-12-21	휴먼 게놈 사이언시즈, 인코포레이티드	종양괴사인자-γ
FR2726471B1 (fr)	1994-11-07	1997-01-31	Pf Medicament	Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AT403167B (de) *	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
EP0796335A1 (en)	1994-12-07	1997-09-24	Bionebraska, Inc.	Production of peptides using recombinant fusion protein constructs
AU4415796A (en)	1994-12-07	1996-06-26	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
DE69534265T2 (de) *	1994-12-12	2006-05-04	Beth Israel Deaconess Medical Center, Inc., Boston	Chimäre zytokine und ihre verwendung
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
JPH10511365A (ja)	1994-12-23	1998-11-04	ノボノルディスクアクティーゼルスカブ	遅延性ｇｌｐ−１組成物
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
WO1996034095A1 (en)	1995-04-27	1996-10-31	Human Genome Sciences, Inc.	Human tumor necrosis factor receptors
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
AU5724996A (en)	1995-05-05	1996-11-21	Eli Lilly And Company	Single chain insulin with high bioactivity
CN1125082C (zh)	1995-05-05	2003-10-22	人类基因组科学公司	人类趋化因子β－8,趋化因子β－1和巨噬细胞炎性蛋白－4
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US5741815A (en) *	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	腎機能改善剤
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
AU7473096A (en)	1995-11-02	1997-05-22	Schering Corporation	Continuous low-dose cytokine infusion therapy
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
CA2246431A1 (en)	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (de)	1996-02-28	1997-09-04	Bayer Ag	Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PL187095B1 (pl)	1996-03-01	2004-05-31	Novo Nordisk As	Peptyd, kompozycja farmaceutyczna zawierająca peptyd, zastosowanie peptydu oraz zastosowanie frakcji HPLC ekstraktu nowotworu glukagonoma
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (ja) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	メタノール代謝系を有する微生物の培養法
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
DK0889949T3 (da)	1996-03-13	2003-09-22	Delta Biotechnology Ltd	Fermenteringskontrol
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997033998A1 (en)	1996-03-14	1997-09-18	The Immune Response Corporation	Targeted delivery of genes encoding interferon
CA2248136A1 (en)	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Human endometrial specific steroid-binding factor i, ii and iii
JP2000508522A (ja)	1996-03-22	2000-07-11	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	アポトーシス誘導分子ｉｉ
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
WO1997039132A1 (en)	1996-04-16	1997-10-23	University Of Miami	Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
AU2405297A (en) *	1996-04-23	1997-11-12	Chugai Seiyaku Kabushiki Kaisha	Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
DK0914116T3 (da) *	1996-05-22	2000-11-20	Protarga Inc	Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
JP3553970B2 (ja) *	1996-06-11	2004-08-11	ロシュダイアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	組換え血液凝固プロテアーゼ
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
EP0935001B2 (en)	1996-07-15	2011-08-10	Chugai Seiyaku Kabushiki Kaisha	Novel vegf-like factors
MY120425A (en)	1996-07-26	2005-10-31	Novartis Ag	Fusion polypeptides
AU3972797A (en)	1996-08-02	1998-02-25	Zymogenetics Inc.	Testis-specific insulin homolog polypeptides
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
DE69738749D1 (de)	1996-08-16	2008-07-17	Schering Corp	Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
KR20010102191A (ko)	1996-08-16	2001-11-15	벤슨 로버트 에이치.	인간의 엔도킨 알파 단백질
DK0956339T3 (da)	1996-08-23	2006-01-30	Licentia Oy	Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
WO1998011136A1 (en)	1996-09-09	1998-03-19	Novo Nordisk A/S	A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
WO1998012344A1 (en) *	1996-09-18	1998-03-26	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
KR100628846B1 (ko)	1996-10-18	2006-09-29	제넨테크, 인크.	항-ＥｒｂＢ２ 항체
WO1998017281A1 (en)	1996-10-24	1998-04-30	Vion Pharmaceuticals, Inc.	MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS
EP0939804B2 (en)	1996-10-25	2011-06-15	Human Genome Sciences, Inc.	NEUTROKINE alpha
JPH10134761A (ja)	1996-10-30	1998-05-22	Ebara Corp	イオン注入装置及びイオン注入方法
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1306092A3 (en)	1996-11-05	2003-05-07	Eli Lilly & Company	Use of GLP-1 and analogs administered peripherally, in regulation of obesity
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
WO1998020895A1 (en)	1996-11-12	1998-05-22	Novo Nordisk A/S	Use of glp-1 peptides
AU5702298A (en)	1996-12-03	1998-06-29	Abgenix, Inc.	Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
AU6238698A (en)	1997-01-14	1998-08-03	Human Genome Sciences, Inc.	Tumor necrosis factor receptor 5
AU5549998A (en)	1997-01-24	1998-08-18	Novo Nordisk A/S	Synthetic leader peptide sequences
AU6250098A (en)	1997-01-28	1998-08-18	Human Genome Sciences, Inc.	Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
AU5773798A (en)	1997-01-29	1998-08-18	Polymasc Pharmaceuticals Plc	Pegylation process
AU746826B2 (en)	1997-02-13	2002-05-02	Regents Of The University Of California, The	Production of mature proteins in plants
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en)	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
WO2001012775A2 (en)	1999-08-17	2001-02-22	Human Genome Sciences, Inc	25 human secreted proteins
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
CA2283834A1 (en)	1997-03-31	1998-10-08	James Arthur Hoffmann	Glucagon-like peptide-1 analogs
DK0970126T3 (da)	1997-04-14	2001-08-13	Micromet Ag	Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
AR012448A1 (es)	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
AU7705198A (en)	1997-05-30	1998-12-30	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU7830398A (en)	1997-06-11	1998-12-30	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr9
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
EP0902085B1 (en)	1997-09-01	2003-12-03	Aventis Pharma Deutschland GmbH	Recombinant human erythropoietin with advantageous glycosylation profile
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1136075B1 (en)	1997-09-21	2003-01-15	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
IL135186A0 (en)	1997-09-23	2001-05-20	Rentschler Biotechnologie Bmgh	LIQUID INTERFERON-β FORMULATIONS
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1042342A4 (en) *	1997-10-09	2003-04-09	Human Genome Sciences Inc	53 PROTEINS OF HUMAN ORIGIN
ES2303358T3 (es)	1997-11-03	2008-08-01	Human Genome Sciences, Inc.	Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
BR9813391C1 (pt)	1997-12-03	2021-05-25	Roche Diagnostics Gmbh	processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo
AU1617399A (en)	1997-12-05	1999-06-28	Eli Lilly And Company	Glp-1 formulations
ATE267215T1 (de)	1997-12-08	2004-06-15	Lexigen Pharm Corp	Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
ES2216335T3 (es) *	1997-12-08	2004-10-16	Bristol-Myers Squibb Company	Nuevas sales de metformina y procedimiento.
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (ko)	1997-12-29	2000-05-01	김충환	사람 인슐린 전구체의 제조방법
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
AU759058C (en)	1998-02-13	2005-09-15	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
EP1060191B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Derivatives of glp-1 analogs
AU2612599A (en)	1998-03-13	1999-10-11	Novo Nordisk A/S	Stabilized aqueous peptide solutions
AU3087599A (en)	1998-03-19	1999-10-11	Bionebraska, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (de)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (en)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Novel microsphere composition
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
CN1119352C (zh)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	人血清白蛋白在毕赤酵母中的表达与纯化
PT956861E (pt) *	1998-05-15	2002-08-30	Schering Corp	Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1419783A3 (en)	1998-06-12	2005-01-12	Amylin Pharmaceuticals, Inc.	Use of a composition comprising an exendin or a compound derived therefrom and a pharmaceutical carrier
CA2330527A1 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corporation	Erythropoietin analog-human serum albumin fusion
CN1105727C (zh)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	重组人血清白蛋白的生产方法
MXPA00012842A (es)	1998-06-24	2004-06-22	Univ Emory	Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
AU758496B2 (en)	1998-06-30	2003-03-20	Novo Nordisk A/S	Seeding crystals for the preparation of peptides or proteins
AU8508398A (en)	1998-07-15	2000-02-07	Wisconsin Alumni Research Foundation	Treatment of diabetes with synthetic beta cells
EP1100530B1 (en)	1998-07-31	2003-10-08	Novo Nordisk A/S	In-vitro stimulation of beta cell proliferation
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US7056734B1 (en)	1998-08-10	2006-06-06	The United States Of America As Represented By The Department Of Health And Human Services, Nih	Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
WO2000012116A1 (en)	1998-08-28	2000-03-09	Eli Lilly And Company	Method for administering insulinotropic peptides
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
WO2000023094A2 (en)	1998-10-16	2000-04-27	Immunex Corporation	Methods of inhibiting platelet activation and recruitment
CA2345882C (en)	1998-10-23	2011-02-01	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
DE69936351T2 (de)	1998-10-30	2008-02-21	Novozymes A/S	Glykosylierte proteine mit reduzierter allergenität
CA2352538A1 (en)	1998-11-30	2000-06-08	Eli Lilly And Company	Erythropoietic compounds
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
ATE307603T1 (de)	1998-12-22	2005-11-15	Lilly Co Eli	Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
US20030009013A1 (en) *	1998-12-30	2003-01-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
WO2000061625A1 (en)	1999-04-09	2000-10-19	Human Genome Sciences, Inc.	48 human secreted proteins
JP2002542183A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	成形可能な乾燥した医薬製剤
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
DE19921537A1 (de)	1999-05-11	2000-11-23	Dieter Hoersch	Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
AU754770B2 (en)	1999-05-17	2002-11-21	Conjuchem Biotechnologies Inc.	Long lasting insulinotropic peptides
HUP0201474A3 (en)	1999-05-19	2002-11-28	Lexigen Pharmaceuticals Corp L	Expression and export of interferon-alpha proteins as fc fusion proteins
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1849475A1 (en)	1999-06-21	2007-10-31	Eli Lilly & Company	Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
JO2291B1 (en) *	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
WO2001005826A2 (en)	1999-07-19	2001-01-25	Gpc Biotech Inc.	Chimeric polypeptides of serum albumin and uses related thereto
US20020048571A1 (en) *	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TWI260321B (en)	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
EP1224309A2 (en)	1999-10-21	2002-07-24	Monsanto Company	Post-translational modification of recombinant proteins produced in plants
AU1226901A (en)	1999-10-22	2001-05-08	Amgen, Inc.	Biodegradable microparticles with novel erythropoietin stimulating protein
AU1130501A (en)	1999-11-03	2001-05-14	Novo Nordisk A/S	Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
CA2324801A1 (en)	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
JP2003514552A (ja)	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	改善された性質を有するエリトロポエチンの形態
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
IL149933A0 (en)	1999-12-06	2002-11-10	Gen Hospital Corp	Pancreatic stem cells and their use in transplantation
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en)	2000-01-18	2003-01-02	Pfizer Products Inc.	Uses of agrp-melanocortin receptor binding modulating compounds
BR0107837A (pt)	2000-01-27	2003-01-14	Lilly Co Eli	Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
WO2001057084A1 (en)	2000-01-31	2001-08-09	Novo Nordisk A/S	Crystallisation of a glp-1 analogue
JP2003526671A (ja)	2000-03-14	2003-09-09	レストラゲン，インコーポレイテッド	幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
EP2067488A1 (en)	2000-04-12	2009-06-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2001255516B2 (en)	2000-04-21	2007-01-18	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
RS51292B (sr) *	2000-05-15	2010-12-31	F. Hoffmann-La Roche Ag.	Nova farmaceutska smeša
WO2001087322A2 (en)	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
DZ3388A1 (fr)	2000-06-16	2001-12-27	Lilly Co Eli	Analogues de peptide 1 du type glucagon
ES2310192T3 (es)	2000-09-18	2009-01-01	Sanos Bioscience A/S	Uso de peptidos glp-2.
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2002045712A1 (en)	2000-12-04	2002-06-13	Biovitrum Ab	Novel method and use
CN1483041A (zh) *	2000-12-07	2004-03-17		Glp-1融合蛋白
EP2186824A3 (en)	2000-12-13	2010-09-22	Eli Lilly & Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US7199217B2 (en)	2000-12-13	2007-04-03	Eli Lilly And Company	Amidated glucagon-like peptide-1
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
KR100399337B1 (ko)	2001-02-07	2003-09-26	드림바이오젠 주식회사	단백질의 무세포 번역후수식법
EP1949908A1 (en)	2001-03-07	2008-07-30	Novo Nordisk A/S	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en)	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050054051A1 (en)	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (en)	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
US20030143191A1 (en)	2001-05-25	2003-07-31	Adam Bell	Chemokine beta-1 fusion proteins
EP1542712A2 (en)	2001-06-01	2005-06-22	Eli Lilly And Company	Glp-1 formulations with protracted time action
EP1397124B1 (fr)	2001-06-20	2006-11-29	Merck Sante	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
DK1412384T3 (da)	2001-06-28	2008-04-28	Novo Nordisk As	Stabil formulering af modificeret GLP-1
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP1572885A2 (en)	2001-08-08	2005-09-14	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
EP1423136A4 (en)	2001-08-10	2007-07-25	Epix Pharm Inc	POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
MXPA04001525A (es)	2001-08-23	2004-05-31	Lilly Co Eli	Analogos de peptido -1 similar al glucagon.
WO2003030821A2 (en) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
MXPA04003333A (es) *	2001-10-10	2006-02-22	Neose Technologies Inc	Remodelado y glicoconjugacion de peptidos.
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
EP1458860A2 (en)	2001-12-21	2004-09-22	Nexia Biotechnologies, Inc.	Production of butyrylcholinesterases in transgenic mammals
WO2003076567A2 (en)	2002-03-05	2003-09-18	Eli Lilly And Company	Heterologous g-csf fusion proteins
MXPA04012496A (es) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
CN1241946C (zh) *	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2380759T3 (es) *	2003-02-27	2012-05-18	Baxter International Inc.	Método para la inactivación certificable de patógenos por irradiación en un fluido biológico
DK1641823T3 (da)	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1-analog fusionsproteiner
KR101184391B1 (ko)	2004-02-09	2013-03-14	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
MX2008001865A (es)	2005-08-12	2008-04-15	Human Genome Sciences Inc	Proteinas de fusion de albumina.
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
US8334365B2 (en)	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
SI2717898T1 (sl) *	2011-06-10	2019-07-31	Bioverativ Therapeutics Inc.	Spojine prokoagulantov in metode za njihovo uporabo

2001
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Application Discontinuation
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en active Application Filing
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Application Discontinuation
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Application Discontinuation
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Application Discontinuation
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en active Application Filing
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en active Application Filing
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
2005
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Lifetime
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
2016
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2213743A1 (en)	2010-08-04
US20040171123A1 (en)	2004-09-02
CA2405557A1 (en)	2001-10-25
JP2003531590A (ja)	2003-10-28
EP1278544A2 (en)	2003-01-29
CA2405525A1 (en)	2001-10-25
EP2267026A1 (en)	2010-12-29
WO2001079271A1 (en)	2001-10-25
US7482013B2 (en)	2009-01-27
US9821039B2 (en)	2017-11-21
US20120252732A1 (en)	2012-10-04
US20120141449A1 (en)	2012-06-07
CA2405557C (en)	2013-09-24
WO2001079443A3 (en)	2002-02-21
DK2236152T3 (da)	2014-07-07
EP1274719A4 (en)	2004-05-19
US20080267962A1 (en)	2008-10-30
US7785599B2 (en)	2010-08-31
CA2405550A1 (en)	2001-10-25
EP1274720A1 (en)	2003-01-15
US20090285816A9 (en)	2009-11-19
EP1274720A4 (en)	2004-08-18
WO2001079444A2 (en)	2001-10-25
US20080269128A1 (en)	2008-10-30
EP1278767A1 (en)	2003-01-29
EP2298355A3 (en)	2011-06-29
AU2001261024A1 (en)	2001-10-30
US20100189686A1 (en)	2010-07-29
EP2311872A1 (en)	2011-04-20
US6994857B2 (en)	2006-02-07
EP2236152A1 (en)	2010-10-06
JP2011217750A (ja)	2011-11-04
WO2001079442A3 (en)	2002-06-06
WO2001079443A2 (en)	2001-10-25
AU2001259063A1 (en)	2001-10-30
US20040010134A1 (en)	2004-01-15
EP1832599A3 (en)	2007-11-21
EP2067488A1 (en)	2009-06-10
US20120141415A1 (en)	2012-06-07
US20050266532A1 (en)	2005-12-01
AU2001274809A1 (en)	2001-10-30
US20140010798A1 (en)	2014-01-09
US20030125247A1 (en)	2003-07-03
US6926898B2 (en)	2005-08-09
WO2001077137A1 (en)	2001-10-18
EP1276856A4 (en)	2004-06-09
AU2001266557A1 (en)	2001-10-23
US9775888B2 (en)	2017-10-03
CA2747325A1 (en)	2001-10-25
JP2003530846A (ja)	2003-10-21
EP1276756A1 (en)	2003-01-22
EP1276756A4 (en)	2004-06-09
WO2001079258A1 (en)	2001-10-25
WO2001079271A9 (en)	2002-02-28
EP2295456A1 (en)	2011-03-16
US20030219875A1 (en)	2003-11-27
EP1276856A1 (en)	2003-01-22
EP2236152B1 (en)	2014-06-04
JP2014057589A (ja)	2014-04-03
US20080269125A1 (en)	2008-10-30
FR16C0043I1 (zh)	2016-12-09
US20070287173A9 (en)	2007-12-13
JP2003530847A (ja)	2003-10-21
US7507414B2 (en)	2009-03-24
JP2004506407A (ja)	2004-03-04
WO2001079480A1 (en)	2001-10-25
WO2001077137A9 (en)	2002-05-02
EP2298355A2 (en)	2011-03-23
EP2206720A1 (en)	2010-07-14
EP2216409B1 (en)	2014-12-03
FR16C0043I2 (fr)	2020-04-10
DK2216409T3 (en)	2015-01-05
EP1274719A2 (en)	2003-01-15
EP1278544A4 (en)	2004-08-18
EP1832599A2 (en)	2007-09-12
US20050266533A1 (en)	2005-12-01
CA2405701A1 (en)	2001-10-25
WO2001079442A2 (en)	2001-10-25
AU2001264563A1 (en)	2001-10-30
CA2405709A1 (en)	2001-10-25
AU2001259066A1 (en)	2001-10-30
JP2003530852A (ja)	2003-10-21
US10080785B2 (en)	2018-09-25
EP1983055A1 (en)	2008-10-22
US8946156B2 (en)	2015-02-03
EP2216409A1 (en)	2010-08-11
EP2357008A1 (en)	2011-08-17
EP1278767A4 (en)	2003-11-12
CA2405563A1 (en)	2001-10-25
EP1276849A4 (en)	2004-06-09
US20080269127A1 (en)	2008-10-30
WO2001079480A9 (en)	2003-09-18
JP2003530839A (ja)	2003-10-21
EP1803730A1 (en)	2007-07-04
US20180200346A1 (en)	2018-07-19
AU2001262942A1 (en)	2001-10-30
ES2484966T3 (es)	2014-08-12
US20140004095A1 (en)	2014-01-02
WO2001079444A3 (en)	2002-05-23
JP2003530838A (ja)	2003-10-21
US6905688B2 (en)	2005-06-14
US20130266553A1 (en)	2013-10-10
US20030171267A1 (en)	2003-09-11
CA2405912A1 (en)	2001-10-18
WO2001079258A9 (en)	2002-02-28
US9849162B2 (en)	2017-12-26
US20110280830A9 (en)	2011-11-17
EP1276849A2 (en)	2003-01-22
EP2275557A1 (en)	2011-01-19
ES2529300T3 (es)	2015-02-18
US20080269126A1 (en)	2008-10-30
US20080261877A1 (en)	2008-10-23
US20030199043A1 (en)	2003-10-23
US20080131399A1 (en)	2008-06-05

Publication	Publication Date	Title
FR16C0043I1 (zh)	2016-12-09
BE2014C035I2 (zh)	2020-08-20
BE2014C009I2 (zh)	2021-02-04
BE2012C026I2 (zh)	2020-12-15
JP2000347946A5 (zh)	2007-05-17
JP2003514716A5 (zh)	2007-12-27
BE2014C025I2 (zh)	2021-01-28
JP2001308306A5 (zh)	2007-06-07
JP2001322262A5 (zh)	2007-07-05
JP2002066009A5 (zh)	2005-06-30
JP2002144601A5 (zh)	2007-10-04
JP2002140082A5 (zh)	2007-12-06
JP2001192159A5 (zh)	2007-01-25
JP2001296412A5 (zh)	2006-07-27
JP2002104386A5 (zh)	2007-11-01
JP2001309113A5 (zh)	2006-02-09
IN189757B (zh)	2003-04-19
IN191958B (zh)	2004-01-24
CN3142225S (zh)	2000-03-15
CN3136792S (zh)	2000-02-02
CN3147660S (zh)	2000-05-10
CN3141400S (zh)	2000-03-08
CN3147984S (zh)	2000-05-17
CN3141005S (zh)	2000-03-08
CN3148873S (zh)	2000-05-24